338990-31-1

Basic information

• Product Name: Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester
• Synonyms: Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester;(2-(((1-chloroethoxy)carbonyl)(Methyl)aMino)pyridin-3-yl)Methyl 2-((tert-butoxycarbonyl)(Methyl)aMino)acetate;N-Methyl-N-(3-[((N-tert-butoxycarbonyl-N-methylamino)acetoxy)methyl]pyridin-2-yl)carbamic acid 1-chloroethyl ester;[N-methyl-N-3-((tert-butoxycarbonylmethylamino)acetoxymethyl)pyridin-2-yl]carbamic acid 1-chloroethyl ester;N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester
• CAS NO: 338990-31-1
• Molecular Formula: C₁₈H₂₆ClN₃O₆
• Molecular Weight: 415.86854
• EINECS: 1592732-453-0
• Mol File: 338990-31-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 507.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.254±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.50±0.10(Predicted)
• CAS DataBase Reference: Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester(338990-31-1)
• EPA Substance Registry System: Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester(338990-31-1)

Safety Data

• Hazardous Substances Data: 338990-31-1(Hazardous Substances Data)

Usage

General Description

The chemical "Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-Methyl-, [2-[[(1-chloroethoxy)carbonyl]MethylaMino]-3-pyridinyl]Methyl ester" is a complex compound with several functional groups. It contains a glycine moiety, with a protective group of 1,1-diMethylethoxy and N-[(1-chloroethoxy)carbonyl]MethylaMino attached to the N-Methyl group. Additionally, it has an ester group connected to a 3-pyridinylMethyl moiety. This chemical may have applications in pharmaceuticals or organic synthesis due to its unique structure and functional groups, and it would likely require extensive characterization and testing for specific uses.

Upstream product

• 13734-36-6 N-(tert-butoxycarbonyl)sarcosine 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 32399-12-5 2-(N-methylamino)-3-hydroxymethylpyridine 
• 338990-70-8 tert-butyl 2-(methylamino)pyridine-3-carboxylate 
• 232951-83-6 tert-butyl 2-chloropyridine-3-carboxylate 
• 2942-59-8 2-chloronicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 

Downstream Products

• 946075-13-4 1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[1-({methyl[3-({[2-(methylamino)acetyl]oxy}methyl)pyridin-2-yl]carbamoyl}oxy)ethyl]-1H-1,2,4-triazol-4-ium hydrogensulfate 
• 338990-63-9 1-[[N-methyl-N-3-[(t-butoxycarbonylmethylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]ethyl-1-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-yl]butyl]-1H-[1,2,4]triazol-4-ium chloride 

Relevant articles and documents

Prodrugs of baloxvir and derivatives thereof and preparation method and application of prodrugs

The present invention provides a compound having a structure represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof, where X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, (R9) m in the formula (I) are defined as in the description and claims of the present invention. The compound is a prodrug of baloxavir and a derivative thereof, and the bioavailability of the compound is greatly improved compared with the bioavailability of the existing baloxavir marboxil. The compound is better than Baloxavir marboxil in the aspects of reducing the dosage, reducing the side effect of the medicine and improving the medicine effect, and can be used as a medicine for treating and/or preventing influenza virus infectious diseases.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.

N-substituted carbamoyloxyalkyl-azolium derivatives

N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.